Zhejiang Doer Biologics has concluded the patient recruitment in P-Ib/IIa trial, the results of which are expected in early 2025
The P-Ib/IIa trial is to determine the safety, tolerability & PK/PD of DR10624 (SC) vs PBO in obese adults (BMI: 30-45kg/m^2) having modest hypertriglyceridemia (fasting triglyceride: ≥150mg/dL & <500 mg/dL at screening) for 12wks. Trial will also assess the drug’s effect on serum lipids, liver fat & body weight
DR10624, developed using Doer Bio’s MultipleBody platform, is a long-acting tri-specific agonist targeting FGF21R, GLP-1R & GCGR that showed its potential to reduce body weight, normalize blood lipids & improve liver function in preclinical studies
Ref: PR Newswire | Image: Zhejiang Doer Biologics
Related News:- Neurobo Pharmaceuticals Reports First Patient Dosing in P-I Study of DA-1726 to Treat Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
